AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12364427 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg Nutropin Depot
Number of subjects: 25
Study 12364427 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg Nutropin Depot
Number of subjects: 25
Study 12364427 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose Nutropin Depot
Number of subjects: 25
Study 12364427 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses Nutropin Depot
Number of subjects: 25
Study 9923825 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg hydroxyethylrutosiden given orally four times daily (group A)
Number of subjects: 85
Study 9923825 — intervention group
Group type: COMPARATOR
Intervention: No hydroxyethylrutosiden (group B)
Number of subjects: 85
Study 9923825 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study 7793451 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (4 micrograms/kg body weight per day)
Number of subjects: 25
Study 7793451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1776351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous CO2 (succinate + sodium bicarbonate = Kao Bub; 1400 mg CO2 per kg water)
Number of subjects: 15
Study 1776351 — intervention group
Group type: COMPARATOR
Intervention: Fresh water
Number of subjects: 15
Study 7295467 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 31899024 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid (TXA)
Number of subjects: 38
Study 31899024 — intervention group
Group type: COMPARATOR
Intervention: Topical Oxymetazoline
Number of subjects: 38
Study 30732134 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin/dexamethasone eye drops
Number of subjects: 409
Study 30732134 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin/dexamethasone ointment
Number of subjects: 409
Study 30732134 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 409
Study 29880851 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized placement into a family caregiving environment during the infant/toddler period
Number of subjects: 0
Study 29880851 — intervention group
Group type: COMPARATOR
Intervention: Prolonged institutional care
Number of subjects: 0
Study 25759418 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 10% spray
Number of subjects: 200
Study 25759418 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 200
Study 23887339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 294
Study 22835779 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced total body CT scan (head to pelvis) during the primary survey
Number of subjects: 0
Study 22835779 — intervention group
Group type: COMPARATOR
Intervention: Conventional trauma imaging protocols supplemented with selective CT scanning
Number of subjects: 0
Study 19559353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphotropic nanoparticle enhanced MRI (LNMRI) using superparamagnetic nanoparticle ferumoxtran-10
Number of subjects: 26
Study 19559353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphotropic nanoparticle enhanced MRI (LNMRI)
Number of subjects: 26
Study 18162137 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mcg fluticasone propionate twice daily
Number of subjects: 260
Study 18162137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 15817593 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus CMF chemotherapy (early, delayed, or both)
Number of subjects: 2881
Study 15817593 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 2881
Study 12418594 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of oral prednisolone (40 mg daily)
Number of subjects: 44
Study 12418594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10626612 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-based intervention including principles derived from the health belief model
Number of subjects: 244
Study 10626612 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 244
Study 7560625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing with a 100-ms AV delay
Number of subjects: 12
Study 7560625 — intervention group
Group type: COMPARATOR
Intervention: Backup mode (VVI at 40 beats/min)
Number of subjects: 12
Study 7560625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing (VDD mode)
Number of subjects: 12
Study 2137901 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g per day of 85 percent eicosapentaenoic and docosahexaenoic acids
Number of subjects: 156
Study 2137901 — intervention group
Group type: COMPARATOR
Intervention: 6 g per day of corn oil
Number of subjects: 156
Study 2137901 — intervention group
Group type: COMPARATOR
Intervention: Comparison between fish oil and corn oil
Number of subjects: 156
Study 512005 — intervention group
Group type: EXPERIMENTAL
Intervention: Exaggerated attending to manifestations of anxiety
Number of subjects: 34
Study 512005 — intervention group
Group type: EXPERIMENTAL
Intervention: Exaggerated relevant anxiety response
Number of subjects: 34
Study 512005 — intervention group
Group type: EXPERIMENTAL
Intervention: Exaggerated irrelevant anxiety response
Number of subjects: 34
Study 512005 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined exaggerated consequence of anxiety
Number of subjects: 34
Study 512005 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 34
Study 31039070 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 720
Study 31039070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 720
Study 31039070 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 720
Study 30414782 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB/MenACWY
Number of subjects: 750
Study 30414782 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB
Number of subjects: 750
Study 30414782 — intervention group
Group type: COMPARATOR
Intervention: MenACWY
Number of subjects: 750
Study 26402722 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and personal contact with individuals with CLP
Number of subjects: 189
Study 26402722 — intervention group
Group type: COMPARATOR
Intervention: Information only
Number of subjects: 189
Study 24994571 — intervention group
Group type: EXPERIMENTAL
Intervention: SVV-based goal-directed therapy (GDT)
Number of subjects: 80
Study 24994571 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid management (control)
Number of subjects: 80
Study 20491816 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic biphasic calcium phosphate (BCP)
Number of subjects: 11
Study 20491816 — intervention group
Group type: COMPARATOR
Intervention: Deproteinized bovine bone (DBB)
Number of subjects: 11
Study 20491816 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BCP and DBB
Number of subjects: 11
Study 20837684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy with liquid nitrogen every two weeks
Number of subjects: 240
Study 20837684 — intervention group
Group type: COMPARATOR
Intervention: Topical salicylic acid self-application daily
Number of subjects: 240
Study 20837684 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see approach
Number of subjects: 240
Study 20837684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy with liquid nitrogen every two weeks (for common warts)
Number of subjects: 240
Study 20837684 — intervention group
Group type: COMPARATOR
Intervention: Topical salicylic acid self-application daily (for common warts)
Number of subjects: 240
Study 20837684 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see approach (for common warts)
Number of subjects: 240
Study 20837684 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy, topical salicylic acid, wait-and-see (for plantar warts)
Number of subjects: 240
Study 18579806 — intervention group
Group type: EXPERIMENTAL
Intervention: l-dopa/decarboxylase inhibitor (DDCI)
Number of subjects: 782
Study 18579806 — intervention group
Group type: COMPARATOR
Intervention: bromocriptine
Number of subjects: 782
Study 18579806 — intervention group
Group type: COMPARATOR
Intervention: l-dopa/DDCI plus selegiline
Number of subjects: 782
Study 16150199 — intervention group
Group type: EXPERIMENTAL
Intervention: Shugan Shuru Granule (SSG)
Number of subjects: 66
Study 16150199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 66
Study 12390953 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/d, titrated to 20 mg/d and then 40 mg/d)
Number of subjects: 173
Study 12390953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 10197493 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL) followed by one or two sessions of sclerotherapy
Number of subjects: 50
Study 10197493 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy with 5% ethanolamine oleate
Number of subjects: 50
Study 7776775 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 g alpha‐ketoglutarate added to blood cardioplegia for intermittent antegrade intracoronary perfusion
Number of subjects: 24
Study 7776775 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alpha‐ketoglutarate)
Number of subjects: 24
Study 2178428 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler flow velocity waveform analysis at 24 weeks' gestation
Number of subjects: 535
Study 2178428 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical artery systolic to diastolic ratios at 24, 28, and 34 weeks' gestation
Number of subjects: 535
Study 2178428 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler systolic to diastolic ratios
Number of subjects: 535
Study 2178428 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler systolic to diastolic ratios as primary screening tests
Number of subjects: 535
Study 7234455 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase of the menstrual cycle
Number of subjects: 46
Study 7234455 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Norgestrel (2.5 mg/die)
Number of subjects: 46
Study 7234455 — intervention group
Group type: COMPARATOR
Intervention: Estradiolvalerate (5 mg/die)
Number of subjects: 46
Study 7234455 — intervention group
Group type: COMPARATOR
Intervention: Mesterolone (100 mg/die)
Number of subjects: 46
Study 7234455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 31574796 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 40
Study 31574796 — intervention group
Group type: COMPARATOR
Intervention: Cleaning of the tongue with a tongue scraper
Number of subjects: 40
Study 28633147 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - 2 doses of 15 mg/kg intravenous TXA dissolved in 100 mL of saline, administered over 10 minutes; 1 dose before incision, 1 dose at wound closure.
Number of subjects: 138
Study 28633147 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 100 mL of saline solution administered in a similar fashion to TXA.
Number of subjects: 138
Study 25298165 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5mg once daily and metformin (uptitrated to 2000mg/day maximum)
Number of subjects: 316
Study 25298165 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin monotherapy
Number of subjects: 316
Study 25298165 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin and metformin combination therapy
Number of subjects: 316
Study 23541974 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-rate nonsustained ventricular tachycardia (RR-NSVT)
Number of subjects: 811
Study 21777700 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 0
Study 21777700 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulant (OAC)
Number of subjects: 0
Study 19114612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 5
Study 19114612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 19114612 — intervention group
Group type: COMPARATOR
Intervention: Metformin XR
Number of subjects: 5
Study 16505738 — intervention group
Group type: EXPERIMENTAL
Intervention: Information, education, and communication (IEC) interventions; condom social marketing (CSM); voluntary counseling and testing (VCT)
Number of subjects: 0
Study 16505738 — intervention group
Group type: EXPERIMENTAL
Intervention: Public and private sexually transmitted infections treatment
Number of subjects: 0
Study 15311441 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0
Study 15311441 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 0
Study 11028725 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with thoracic epidural analgesia (TEA)
Number of subjects: 30
Study 11028725 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 30
Study 9296318 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg, twice daily for 5 days)
Number of subjects: 8
Study 9296318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8068603 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 20
Study 8068603 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 20
Study 3057476 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 15
Study 3057476 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitoxin
Number of subjects: 15
Study 29396978 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT-2 (10×60‐s cycling at 83% of peak power, two times per week for eight weeks)
Number of subjects: 35
Study 29396978 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT-3 (10×60‐s cycling at 83% of peak power, three times per week for eight weeks)
Number of subjects: 35
Study 29396978 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 35
Study 26219670 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Number of subjects: 210
Study 26219670 — intervention group
Group type: COMPARATOR
Intervention: Open gastrectomy
Number of subjects: 210
Study 23698074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C (Gentian)
Number of subjects: 16279
Study 23698074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C (Roche)
Number of subjects: 16279
Study 23698074 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined creatinine-cystatin C equation (Gentian)
Number of subjects: 16279
Study 23698074 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined creatinine-cystatin C equation (Roche)
Number of subjects: 16279
Study 23698074 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD-EPI eGFR
Number of subjects: 16279
Study 20673569 — intervention group
Group type: COMPARATOR
Intervention: Observation of stimulus (Obs-S)
Number of subjects: 0
Study 20673569 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of stimulus and action (Obs-SA)
Number of subjects: 0
Study 20673569 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical practice (PP)
Number of subjects: 0
Study 18355332 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 35
Study 18355332 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 35
Study 16963663 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (IV administration)
Number of subjects: 6219
Study 16963663 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (subcutaneous administration)
Number of subjects: 6219
Study 16963663 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 6219
Study 16963663 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 6219
Study 12792378 — intervention group
Group type: COMPARATOR
Intervention: cp‐45 vaccine (106 pfu in adults and seropositive children; 104 and 105 pfu in seronegative children; two doses of 104 pfu in infants at 1 or 3 month intervals)
Number of subjects: 145
Study 12792378 — intervention group
Group type: EXPERIMENTAL
Intervention: cp‐45 vaccine (two doses of 104 pfu in infants)
Number of subjects: 145
Study 12792378 — intervention group
Group type: EXPERIMENTAL
Intervention: cp‐45 vaccine
Number of subjects: 145
Study 11089754 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% succinylated modified fluid gelatin (MFG)
Number of subjects: 34
Study 11089754 — intervention group
Group type: COMPARATOR
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 34
Study 8682818 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-knee graded compression stockings
Number of subjects: 177
Study 8682818 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-knee graded compression stockings
Number of subjects: 177
Study 8682818 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stockings)
Number of subjects: 177
Study 1758941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-event glucose ingestion (50 g)
Number of subjects: 13
Study 1758941 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion (identically sweetened and colored)
Number of subjects: 13
Study 6281704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Premarin
Number of subjects: 34
Study 6281704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31823549 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐MIPO
Number of subjects: 120
Study 31823549 — intervention group
Group type: COMPARATOR
Intervention: traditional MIPO
Number of subjects: 120
Study 29037620 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercises for wrist flexors and extensors (6 weeks, home exercises using a bucket filled with water)
Number of subjects: 30
Study 29037620 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention, lifestyle as usual)
Number of subjects: 30
Study 29037620 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (training and control)
Number of subjects: 30
Study 24494297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided acupotomy
Number of subjects: 80
Study 24494297 — intervention group
Group type: COMPARATOR
Intervention: Regular acupotomy
Number of subjects: 80
Study 20966402 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or intensive statin therapy
Number of subjects: 3501
Study 19407678 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-night regimen of 25-microg vaginal estradiol tablet inserted nightly for five nights
Number of subjects: 154
Study 19407678 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 25-microg vaginal estradiol tablet before the test
Number of subjects: 154
Study 19407678 — intervention group
Group type: COMPARATOR
Intervention: No previous estrogen administration (control group)
Number of subjects: 154
Study 17187405 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting octreotide (Sandostatin LAR 30 mg) intramuscularly every 4 weeks
Number of subjects: 120
Study 17187405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 15112861 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of losigamone (600 mg per day)
Number of subjects: 16
Study 15112861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11402636 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacy-based intervention including education on disease, pharmacotherapy, and self-management; inhalation technique assessment and correction.
Number of subjects: 161
Study 11402636 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacy-based intervention.
Number of subjects: 161
Study 11402636 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 161
Study 9669459 — intervention group
Group type: EXPERIMENTAL
Intervention: X‐MS dragees (8 g X per day)
Number of subjects: 188
Study 9669459 — intervention group
Group type: EXPERIMENTAL
Intervention: X‐PD dragees (8 g X per day)
Number of subjects: 188
Study 9669459 — intervention group
Group type: COMPARATOR
Intervention: Control group (no saliva stimulants)
Number of subjects: 188
Study 7716018 — intervention group
Group type: EXPERIMENTAL
Intervention: Water birth
Number of subjects: 32
Study 7716018 — intervention group
Group type: COMPARATOR
Intervention: Conventional birth
Number of subjects: 32
Study 2658606 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cervical examinations and instruction regarding subtle symptoms and signs of preterm labor
Number of subjects: 4595
Study 2658606 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 4595
Study 2658606 — intervention group
Group type: EXPERIMENTAL
Intervention: Year 1 (all patients received preterm birth precautions)
Number of subjects: 4595
Study 2658606 — intervention group
Group type: EXPERIMENTAL
Intervention: Private study patients
Number of subjects: 4595
Study 773391 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 36
Study 773391 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 36
Study 31375503 — intervention group
Group type: EXPERIMENTAL
Intervention: Central monitor position (eye-level on the radiant warmer)
Number of subjects: 30
Study 31375503 — intervention group
Group type: COMPARATOR
Intervention: Peripheral monitor position (above eye-level, wall-mounted)
Number of subjects: 30
Study 31375503 — intervention group
Group type: EXPERIMENTAL
Intervention: Central monitor position
Number of subjects: 30
Study 31375503 — intervention group
Group type: COMPARATOR
Intervention: Peripheral monitor position
Number of subjects: 30
Study 31050986 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test with allergen extracts (Mixture of Weeds and Mixture of Grass)
Number of subjects: 126
Study 31050986 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular investigations for allergen sensitization
Number of subjects: 126
Study 28533290 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate 800 mg/day
Number of subjects: 604
Study 28533290 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 604